StockNews.com Upgrades Kamada (NASDAQ:KMDA) to “Strong-Buy”

StockNews.com upgraded shares of Kamada (NASDAQ:KMDA) from a buy rating to a strong-buy rating in a research report released on Thursday morning.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Kamada in a research note on Thursday, March 6th.

Kamada Trading Down 0.7 %

Shares of Kamada stock opened at $7.18 on Thursday. The stock has a 50-day moving average price of $7.23 and a 200 day moving average price of $6.22. The company has a market cap of $412.71 million, a P/E ratio of 25.64, a P/E/G ratio of 0.97 and a beta of 0.97. Kamada has a 1 year low of $4.74 and a 1 year high of $9.15.

Kamada Announces Dividend

The company also recently declared a — dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be paid a dividend of $0.20 per share. The ex-dividend date of this dividend is Monday, March 17th.

Institutional Investors Weigh In On Kamada

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Plato Investment Management Ltd acquired a new position in shares of Kamada during the 3rd quarter valued at about $117,000. Public Employees Retirement System of Ohio acquired a new position in shares of Kamada during the 3rd quarter valued at about $77,000. JPMorgan Chase & Co. acquired a new position in shares of Kamada during the 4th quarter valued at about $67,000. Geode Capital Management LLC increased its holdings in shares of Kamada by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after acquiring an additional 1,549 shares during the last quarter. Finally, NewEdge Advisors LLC increased its holdings in shares of Kamada by 54.2% during the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after acquiring an additional 8,260 shares during the last quarter. 20.38% of the stock is owned by hedge funds and other institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.